Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

SS-31

Same goal

Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01

SS-31

Longevity · Metabolic / Weight

Vials · 10 / 50 mg

01Protocol

Vials: 10 / 50 mg
Dosing data: Lab reference — not listed

02Quick calculator

03Mechanism of action

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane and is studied for stabilising mitochondrial energy production.

04Study endpoints

MMPOWER-3 (218 adults with primary mitochondrial myopathy, 24 weeks): no improvement vs placebo in 6-minute walk distance or fatigue.
An earlier crossover trial missed its primary endpoint but showed signals in patient-reported outcomes, which supported MMPOWER-3.

05Safety & regulatory findings

Not approved for mitochondrial myopathy; research-grade material is not a medicine.
Generally well tolerated in trials; injection-site reactions were the most common event (80% in the crossover trial), mostly mild.

06Citations

2 references · view